Misplaced Pages

Copper IUD
Photo of a common IUD (Paragard T 380A)
Background
Type	Intrauterine
First use	1970s
Trade names	copper-T, ParaGard, others
AHFS/Drugs.com	FDA Professional Drug Information
Failure rates (first year)
Perfect use	0.6%
Typical use	0.8%
Usage
Duration effect	5–12+ years
Reversibility	rapid
User reminders	Check thread position after each period. Have removed shortly after menopause, if not before.
Clinic review	Annually
Advantages and disadvantages
STI protection	No
Periods	May be heavier and more painful
Benefits	Unnecessary to take any daily action. Emergency contraception if inserted within 5 days
Risks	Small risk of PID in first 20 days following insertion. Rarely, uterine perforation.

A copper intrauterine device (IUD), also known as an intrauterine coil or copper coil or non-hormonal IUD, is a type of intrauterine device which contains copper. It is used for birth control and emergency contraception within five days of unprotected sex. It is one of the most effective forms of birth control with a one-year failure rate around 0.7%. The device is placed in the uterus and lasts up to twelve years. It may be used by women of all ages regardless of whether or not they have had children. Following removal, fertility quickly returns.

Side effects may be heavy menstrual periods, and/or rarely the device may come out. It is less recommended for people at high risk of sexually transmitted infections as it may increase the risk of pelvic inflammatory disease in the first three weeks after insertion. It is recommended for people who don't tolerate or hardly tolerate hormonal contraceptives. If a woman becomes pregnant with an IUD in place removal is recommended. Very rarely, uterine perforation may occur during insertion if not done properly. The copper IUD is a type of long-acting reversible birth control. It primarily works by killing the sperm.

The copper IUD came into medical use in the 1970s. It is on the World Health Organization's List of Essential Medicines. They are used by more than 170 million women globally.

Medical uses

Copper IUDs are a form of long-acting reversible contraception and are one of the most effective forms of birth control available. The type of frame and amount of copper can affect the effectiveness of different copper IUD models. The failure rates for different models vary between 0.1 and 2.2% after 1 year of use. The T-shaped models with a surface area of 380 mm of copper have the lowest failure rates. The TCu 380A (ParaGard) has a one-year failure rate of 0.8% and a cumulative 12-year failure rate of 2.2%. Over 12 years of use, the models with less surface area of copper have higher failure rates. The TCu 220A has a 12-year failure rate of 5.8%. The frameless GyneFix has a failure rate of less than 1% per year. Worldwide, older IUD models with lower effectiveness rates are no longer produced.

Unlike other forms of reversible contraception, the typical use failure rate and the perfect use failure rate for the copper IUDs are the same because the IUD does not depend on user action. A 2008 review of the available T-shaped copper IUDs recommended that the TCu 380A and the TCu 280S be used as the first choice for copper IUDs because those two models have the lowest failure rates and the longest lifespans. The effectiveness of the copper IUD (failure rate of 0.8%) is comparable to tubal sterilization (failure rate of 0.5%) for the first year.

Emergency contraception

It was first discovered in 1976 that the copper IUD could be used as a form of emergency contraception (EC). The copper IUD is the most effective form of emergency contraception. It is more effective than the hormonal EC pills currently available. The pregnancy rate among those using the copper IUD for EC is 0.09%. It can be used for EC up to five days after the act of unprotected sex and does not decrease in effectiveness during the five days. An additional advantage of using the copper IUD for emergency contraception is that it can be used as a form of birth control for 10–12 years after insertion.

Removal and return to fertility

Removal of the copper IUD should also be performed by a qualified medical practitioner. Fertility has been shown to return to previous levels quickly after removal of the device. One study found that the median amount of time from removal to planned pregnancy was three months for those women using the TCu 380Ag.

Side effects

Expulsion: Sometimes, the copper IUD can be spontaneously expelled from the uterus. Expulsion rates can range from 2.2% to 11.4% of users from the first year to the 10th year. The TCu380A may have lower rates of expulsion than other models. Unusual vaginal discharge, cramping or pain, spotting between periods, postcoital (after sex) spotting, dyspareunia, or the absence or lengthening of the strings can be signs of a possible expulsion. If expulsion occurs, the woman is not protected against pregnancy. If an IUD with copper is inserted after an expulsion has occurred, the risk of re-expulsion has been estimated in one study to be approximately one third of cases after one year. Magnetic resonance imaging (MRI) may cause dislocation of a copper IUD, and it is therefore recommended to check the location of the IUD both before and after MRI.

Perforation: Very rarely, the IUD can move through the wall of the uterus. Risk of perforation is mostly determined by the skill of the practitioner performing the insertion. For experienced medical practitioners, the risk of perforation is 1 per 1,000 insertions or less.

Infection: The insertion of a copper IUD poses a transient risk of pelvic inflammatory disease (PID) in the first 21 days after insertion. However, it is a small risk and is attributable to preexisting gonorrhea or chlamydia infection at the time of insertion, and not to the IUD itself. Proper infection prevention procedures have little or no effect on the course of gonorrhea or chlamydia infections but are important in helping protect both clients and providers from infection in general. Such infection prevention practices include washing hands and then putting on gloves, cleaning the cervix and vagina, making minimal contact with non-sterile surfaces (using a no-touch insertion technique), and, after the procedure, washing hands again and then processing instruments. The device itself carries no increased risk of PID beyond the time of insertion.

Cramping: Some women can feel cramping during the IUD insertion process and immediately after as a result of cervix dilation during insertion. Taking NSAIDs before the procedure often reduces discomfort, as the use of a local anaesthetic. Misoprostol 6 to 12 hrs before insertion can help with cervical dilation. Some women may have cramps for 1 to 2 weeks following insertion.

Heavier periods: The copper IUD may increase the amount of blood flow during a woman's menstrual periods. On average, menstrual blood loss may increase by 20–50% after insertion of a copper-T IUD; This symptom may clear up for some women after 3 to 6 months.

Irregular bleeding and spotting: For some women, the copper IUD may cause spotting between periods during the first 3 to 6 months after insertion.

Pregnancy: Although rare, if pregnancy does occur with the copper IUD in place there can be side effects. The risk of ectopic pregnancy to a woman using an IUD is lower than the risk of ectopic pregnancy to a woman using no form of birth control. However, of pregnancies that do occur during IUD use, a higher than expected percentage (3–4%) are ectopic. If pregnancy occurs with the IUD in place there is a higher risk of miscarriage or early delivery. If this occurs and the IUD strings are visible, the IUD should be removed immediately by a clinician. Although the Dalkon Shield IUD was associated with septic abortions (infections associated with miscarriage), other brands of IUD are not. IUDs are also not associated with birth defects.

Some barrier contraceptives protect against STIs. Hormonal contraceptives reduce the risk of developing pelvic inflammatory disease (PID), a serious complication of certain STIs. IUDs, by contrast, do not protect against STIs or PID.

Copper Toxicity: There exists anecdotal evidence linking copper IUDs to cases of copper toxicity.

Contraindications

A category 3 condition indicates conditions where the theoretical or proven risks usually outweigh the advantages of inserting a copper IUD. A category 4 condition indicates conditions that represent an unacceptable health risk if a copper IUD is inserted.

Women should not use a copper IUD if they:

(Category 4)

• Are pregnant or think they may be pregnant
• Have certain uterine abnormalities
• Have malignant gestational trophoblastic disease
• Have or may have an STI
• Have or may have had a pelvic infection within the past three months
• Have pelvic tuberculosis
• Have unexplained abnormal vaginal bleeding
• Have untreated cervical cancer
• Have uterine cancer
• Having a septic pregnancy or abortion

(Category 3)

• Are postpartum between 48 hours and 4 weeks (increased IUD expulsion rate with delayed postpartum insertion). The CDC and WHO criteria differ in their recommendation for women postpartum between 48 hours and 4 weeks. The CDC does not list this as a contraindication.
• Have AIDS (unless clinically well on anti-retroviral therapy)
• Have benign gestational trophoblastic disease
• Have ovarian cancer
• Have very high individual likelihood of exposure to gonorrhea or chlamydial STIs

A full list of contraindications can be found in the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use and the Centers for Disease Control and Prevention (CDC) United States Medical Eligibility Criteria for Contraceptive Use.

Being a nulliparous women (women who have never given birth) is not a contraindication for IUD use. IUDs are safe and acceptable even in young nulliparous women.

Device description

There are a number of models of copper IUDs available around the world. Most copper devices consist of a plastic core that is wrapped in a copper wire. Many of the devices have a T-shape similar to the hormonal IUD. However, there are "frameless" copper IUDs available as well. ParaGard is the only model currently available in the United States. At least three copper IUD models are available in Canada, two of which are slimmer T-shape versions used for women who have not had children. Early copper IUDs had copper around only the vertical stem, but more recent models have copper sleeves wrapped around the horizontal arms as well, increasing effectiveness.

Some newer models also contain a silver core instead of a plastic core to delay copper fragmentation as well as increase the lifespan of the device. The lifespan of the devices range from 3 years to 10 years; however, some studies have demonstrated that the TCu 380A may be effective through 12 years.

Its ATC code is G02BA (WHO).

Insertion

A copper IUD can be inserted at any phase of the menstrual cycle, but the optimal time is right after the menstrual period when the cervix is softest and the woman is least likely to be pregnant. The insertion process generally takes five minutes or less. The procedure can cause cramping or be painful. Before placement of an IUD, a medical history and physical examination by a medical professional is useful to check for any contraindications or concerns. It is also recommended by some clinicians that patients be tested for gonorrhea and chlamydia, as these two infections increase the risk of contracting pelvic inflammatory disease shortly after insertion.

Immediately prior to insertion, the clinician will perform a pelvic exam to determine the position of the uterus. After the pelvic exam, the vagina is held open with a speculum. A tenaculum is used to steady the cervix and uterus. Uterine sounding may be used to measure the length and direction of the cervical canal and uterus in order to decrease the risk of uterine perforation. The IUD is placed using a narrow tube, which is inserted through the cervix into the uterus. Short monofilament plastic/nylon strings hang down from the uterus into the vagina. The clinician will trim the threads so that they only protrude 3 to 4 cm out of the cervix and remain in the upper vagina. The strings allow the patient or clinician to periodically check to ensure the IUD is still in place and to enable easy removal of the device.

The copper IUD can be inserted at any time in a woman's menstrual cycle as long as the woman is not pregnant. An IUD can also be inserted immediately postpartum and post-abortion as long as no infection has occurred. Breastfeeding is not a contraindication for the use of the copper IUD. The IUD can be inserted in women with HIV or AIDS as it does not increase the risk of transmission. Although previously not recommended for nulliparous women (women who have not had children), the IUD is now recommended for most women who are past menarche (their first period), including adolescents.

After the insertion is finished, normal activities such as sex, exercise, and swimming can be performed as soon as it feels comfortable. Strenuous physical activity does not affect the position of the IUD.

Types

Many different types of copper IUDs are currently manufactured worldwide, but availability varies by country. In the United States, only one type of copper IUD is approved for use, while in the United Kingdom, over ten varieties are available. One company, Mona Lisa N.V., offers generic versions of many existing IUDs.

Frameless IUDs

The frameless IUD eliminates the use of the frame that gives conventional IUDs their signature T-shape. This change in design was made to reduce discomfort and expulsion associated with prior IUDs; without a solid frame, the frameless IUD should mold to the shape of the uterus. It may reduce expulsion and discontinuation rates compared to framed copper IUDs.

Gynefix is the only frameless IUD brand currently available. It consists of hollow copper tubes on a polypropylene thread. It is inserted through the cervix with a special applicator that anchors the thread to the fundus (top) of the uterus; the thread is then cut with a tail hanging outside of the cervix, similar to framed IUDs, or looped back into the cervical canal for patient comfort. When this tail is pulled, the anchor is released and the device can be removed. This requires more force than removing a T-shaped IUD and results in comparable discomfort during removal.

Mechanism of action

The copper IUD's primary mechanism of action is to prevent fertilization. Copper acts as a spermicide within the uterus. The presence of copper increases the levels of copper ions, prostaglandins, and white blood cells within the uterine and tubal fluids.

Although not a primary mechanism of action, some experts in human reproduction believe there is sufficient evidence to suggest that IUDs with copper can disrupt implantation, especially when used for emergency contraception. Despite this, there has been no definitive evidence that IUD users have higher rates of embryonic loss than women not using contraception. Therefore, the copper IUD is considered to be a true contraceptive and not an abortifacient.

Usage

Globally, the IUD is the most widely used method of reversible birth control. The most recent data indicates that there are 169 million IUD users around the world. This includes both the nonhormonal and hormonal IUDs. IUDs are most popular in Asia, where the prevalence is almost 30%. In Africa and Europe, the prevalence is around 20%. As of 2009, levels of IUD use in the United States are estimated to be 5.5%. Data in the United States does not distinguish between hormonal and non-hormonal IUDs. In Europe, copper IUD prevalence ranges from under 5% in the United Kingdom to over 10% in Denmark in 2006.

History

According to popular legend, Arab traders inserted small stones into the uteruses of their camels to prevent pregnancy during long desert treks. The story was originally a tall tale to entertain delegates at a scientific conference on family planning; although it was later repeated as truth, it has no known historical basis.

Precursors to IUDs were first marketed in 1902. Developed from stem pessaries (where the stem held the pessary in place over the cervix), the 'stem' on these devices actually extended into the uterus itself. Because they occupied both the vagina and the uterus, this type of stem pessary was also known as an intrauterine device. The use of intrauterine devices was associated with high rates of infection; for this reason, they were condemned by the medical community.

The first intrauterine device (contained entirely in the uterus) was described in a German publication in 1909, although the author appears to have never marketed his product.

In 1929, Ernst Gräfenberg of Germany published a report on an IUD made of silk sutures. He had found a 3% pregnancy rate among 1,100 women using his ring. In 1930, Gräfenberg reported a lower pregnancy rate of 1.6% among 600 women using an improved ring wrapped in silver wire. Unbeknownst to Gräfenberg, the silver wire was contaminated with 26% copper. Copper's role in increasing IUD efficacy would not be recognized until nearly 40 years later.

In 1934, Japanese physician Tenrei Ota developed a variation of Gräfenberg's ring that contained a supportive structure in the center. The addition of this central disc lowered the IUD's expulsion rate. These devices still had high rates of infection, and their use and development were further stifled by World War II politics: contraception was forbidden in both Nazi Germany and Axis-allied Japan. The Allies did not learn of the work by Gräfenberg and Ota until well after the war ended.

The first plastic IUD, the Margulies Coil or Margulies Spiral, was introduced in 1958. This device was somewhat large, causing discomfort to a large proportion of women users, and had a hard plastic tail, causing discomfort to their male partners. The modern colloquialism "coil" is based on the coil-shaped design of early IUDs.

The Lippes Loop, a slightly smaller device with a monofilament tail, was introduced in 1962 and gained in popularity over the Margulies device.

The stainless steel single-ring IUD was developed in the 1970s and widely used in China because of low manufacturing costs. The Chinese government banned production of steel IUDs in 1993 due to high failure rates (up to 10% per year).

Howard Tatum, in the US, conceived the plastic T-shaped IUD in 1968. Shortly thereafter Jaime Zipper, in Chile, introduced the idea of adding copper to the devices to improve their contraceptive effectiveness. It was found that copper-containing devices could be made in smaller sizes without compromising effectiveness, resulting in fewer side effects such as pain and bleeding. T-shaped devices had lower rates of expulsion due to their greater similarity to the shape of the uterus.

The poorly designed Dalkon Shield plastic IUD (which had a multifilament tail) was manufactured by the A. H. Robins Company and sold by Robins in the United States for three and a half years from January 1971 through June 1974, before sales were suspended by Robins on June 28, 1974, at the request of the FDA because of safety concerns following reports of 110 septic spontaneous abortions in women with the Dalkon Shield in place, seven of whom had died. Robins stopped international sales of the Dalkon Shield in April 1975.

Tatum developed many different models of the copper IUD. He created the TCu220 C, which had copper collars as opposed to a copper filament, which prevented metal loss and increased the lifespan of the device. Second-generation copper-T IUDs were also introduced in the 1970s. These devices had higher surface areas of copper, and for the first time consistently achieved effectiveness rates of greater than 99%. The last model Tatum developed was the TCu380A, the model that is most recommended today.

Brands

This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources in this section. Unsourced material may be challenged and removed. (July 2023) (Learn how and when to remove this message)

The Paragard T-380A is an IUD with copper, manufactured and marketed in the United States by The Cooper Companies. It is the only copper-containing intrauterine device approved for use in the U.S. (four hormonal uterine devices, Mirena, Skyla, Liletta, and Kyleena are also approved). The Paragard consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in the removal of the IUD.

The Paragard T 380A was developed in the 1970s by the Population Council and Finishing Enterprises Inc. (FEI). The Population Council's Paragard new drug application (NDA) was approved by the U.S. Food and Drug Administration (FDA) and FEI began manufacturing it for distribution outside the United States in 1984. GynoPharma (originally GynoMed) began marketing it in the U.S. in May 1988. On August 2, 1995, Ortho-McNeil acquired GynoPharma and began marketing Paragard in the U.S. On January 1, 2004, FEI Women's Health acquired the patent from the Population Council and U.S. marketing rights from Ortho-McNeil. On November 10, 2005, Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, acquired FEI Women's Health and Paragard. On July 18, 2008, it was announced that Teva Pharmaceutical Industries Ltd. would acquire Barr Pharmaceuticals.

On November 1, 2017, The Cooper Companies acquired Paragard from Teva Pharmaceutical Industries for approximately $1.1 billion.

The original FDA approval of Paragard in 1984 was for 4 years continuous use, this was later extended to 6 years in 1989, then 8 years in 1991, then 10 years in 1994. (ATC code G02BA02 (WHO))

References

1. ^ Goodwin TM, Montoro MN, Muderspach L, Paulson R, Roy S (2010). Management of Common Problems in Obstetrics and Gynecology (5 ed.). John Wiley & Sons. pp. 494–496. ISBN 978-1-4443-9034-6. Archived from the original on 2017-11-05.
2. ^ Trussell J (2011). "Contraceptive efficacy" (PDF). In Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 779–863. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. Archived (PDF) from the original on 2017-02-15.
3. ^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 370–2. hdl:10665/44053. ISBN 9789241547659.
4. ^ Wipf J (2015). Women's Health, An Issue of Medical Clinics of North America. Elsevier Health Sciences. p. 507. ISBN 978-0-323-37608-2. Archived from the original on 2017-09-24.
5. "IUD Birth Control Info About Mirena & ParaGard IUDs". www.plannedparenthood.org. Archived from the original on 4 January 2021. Retrieved 22 March 2018.
6. ^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. pp. 557–559. ISBN 978-0-85711-156-2.
7. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
8. Speroff L, Darney PD (2011). A Clinical Guide for Contraception. Lippincott Williams & Wilkins. p. 243. ISBN 978-1-60831-610-6. Archived from the original on 2017-11-05.
9. Schäfer-Korting M (2010). Drug Delivery. Springer Science & Business Media. p. 290. ISBN 978-3-642-00477-3. Archived from the original on 2017-11-05.
10. ^ Winner, B, Peipert, JF, Zhao, Q, Buckel, C, Madden, T, Allsworth, JE, Secura, GM. (2012). "Effectiveness of Long-Acting Reversible Contraception". New England Journal of Medicine. 366 (21): 1998–2007. doi:10.1056/NEJMoa1110855. PMID 22621627. S2CID 16812353. Archived from the original on 2020-08-17. Retrieved 2019-08-18.
11. ^ Kulier R, O'Brien P, Helmerhorst FM, Usher-Patel M, d'Arcangues C (2008). "Copper containing, framed intra-uterine devices for contraception (Review)". Cochrane Database of Systematic Reviews (4): CD005347. doi:10.1002/14651858.CD005347.PUB3. PMID 17943851.
12. O'Brien PA, Marfleet C (25 January 2005). "Frameless versus classical intrauterine device for contraception". The Cochrane Database of Systematic Reviews (1): CD003282. doi:10.1002/14651858.CD003282.pub2. ISSN 1469-493X. PMID 15674904.
13. ^ Treiman K, Liskin L, Kols A, Rinehart W (December 1995). "IUDs—an update" (PDF). Population Reports. Series B, Intrauterine Devices (6). Baltimore: Johns Hopkins School of Public Health, Population Information Program: 1–35. PMID 8724322. Archived (PDF) from the original on October 29, 2013. Retrieved July 9, 2006.
14. ^ The Guttmacher Institute (2012). "Contraceptive Use in the United States". Archived from the original on 2013-10-04. Retrieved 2013-10-04.
15. Bartz D, Greenberg JA (2008). "Sterilization in the United States". Reviews in Obstetrics & Gynecology. 1 (1): 23–32. PMC 2492586. PMID 18701927.
16. Committee On Practice Bulletins-Gynecology LA (November 2017). "Practice Bulletin No. 186" (PDF). Obstetrics & Gynecology. 130 (5): e251–e269. doi:10.1097/AOG.0000000000002400. PMID 29064972. S2CID 35477591. Archived from the original on 2021-08-28. Retrieved 2019-06-20.
17. Lippes, J, Malik, T, Tatum, HJ (1976). "The postcoital copper-T". Adv Plan Parent. 11 (1): 24–9. PMID 976578.
18. Cheng, L, Gulmezoglu, AM, Piaggio, G, Ezcurra, E, Van Look, PF (2008). Cheng L (ed.). "Interventions for emergency contraception". Cochrane Database of Systematic Reviews (2): CD001324. doi:10.1002/14651858.cd001324.pub3. PMID 18425871.
19. ^ Cleland K, Zhu H, Goldstruck N, Cheng L, Trussel T (2012). "The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience". Human Reproduction. 27 (7): 1994–2000. doi:10.1093/humrep/des140. PMC 3619968. PMID 22570193.
20. ^ Dean G, Schwarz EB (2011). "Intrauterine contraceptives (IUCs)". In Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 147–191. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. p.150:

    Mechanism of action
    Although the precise mechanism of action is not known, currently available IUCs work primarily by preventing sperm from fertilizing ova. IUCs are not abortifacients: they do not interrupt an implanted pregnancy. Pregnancy is prevented by a combination of the "foreign body effect" of the plastic or metal frame and the specific action of the medication (copper or levonorgestrel) that is released. Exposure to a foreign body causes a sterile inflammatory reaction in the intrauterine environment that is toxic to sperm and ova and impairs implantation. The production of cytotoxic peptides and activation of enzymes lead to inhibition of sperm motility, reduced sperm capacitation and survival, and increased phagocytosis of sperm. The TCu380A causes an increase in copper ions, enzymes, prostaglandins, and white blood cells (macrophages) in uterine and tubal fluids; these impair sperm function and prevent fertilization.
    p. 162:
    Table 7-1. Myths and misconceptions about IUCs
    Myth: IUCs are abortifacients. Fact: IUCs prevent fertilization and are true contraceptives.

21. Belhadj, H, et al. (1986). "Recovery of fertility after use of the Levonorgestrel 20 mcg/d or copper T 380 Ag intrauterine device". Contraception. 34 (3): 261–267. doi:10.1016/0010-7824(86)90007-7. PMID 3098498.
22. Kaneshiro B, Aeby T (2010). "Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device". International Journal of Women's Health. 2: 211–220. doi:10.2147/ijwh.s6914. PMC 2971735. PMID 21072313.
23. Bahamondes L, Díaz J, Marchi NM, Petta CA, Cristofoletti ML, Gomez G (November 1995). "Performance of copper intrauterine devices when inserted after an expulsion". Hum. Reprod. 10 (11): 2917–8. doi:10.1093/oxfordjournals.humrep.a135819. PMID 8747044.
24. Berger-Kulemann V, Einspieler H, Hachemian N, Prayer D, Trattnig S, Weber M, Ba-Ssalamah A (2013). "Magnetic Field Interactions of Copper-Containing Intrauterine Devices in 3.0-Tesla Magnetic Resonance Imaging: In Vivo Study". Korean Journal of Radiology. 14 (3): 416–22. doi:10.3348/kjr.2013.14.3.416. ISSN 1229-6929. PMC 3655294. PMID 23690707.
25. ^ WHO Scientific Group on the Mechanism of Action Safety and Efficacy of Intrauterine Devices, World Health Organization (1987). Mechanism of action, safety and efficacy of intrauterine devices. Geneva: World Health Organization. hdl:10665/38182. ISBN 9241207531. World Health Organization technical report series; no. 753.
26. ^ Mohllajee AP, Curtis KM, Peterson HB (2006). "Does insertion of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review". Contraception. 73 (2): 143–153. doi:10.1016/j.contraception.2005.08.007. PMID 16413845. Archived from the original on 2020-02-06. Retrieved 2020-09-30.
27. ^ "Infection Prevention Practices for IUD Insertion and Removal". Archived from the original on 2010-01-01. By the United States Agency for International Development (USAID). Retrieved on Feb 14, 2010
28. ^ Hutten-Czapski P, Goertzen J (2008). "The occasional intrauterine contraceptive device insertion" (PDF). Can J Rural Med. 13 (1): 31–5. PMID 18208650. Archived from the original (PDF) on 2016-08-14. Retrieved 2009-01-22.
29. ^ World Health Organization (2015). Medical eligibility criteria for contraceptive use (5th ed.). Geneva: World Health Organization. hdl:10665/181468. ISBN 9789241549158.
30. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O (1992). "Intrauterine devices and pelvic inflammatory disease: an international perspective". Lancet. 339 (8796): 785–8. doi:10.1016/0140-6736(92)91904-M. PMID 1347812. S2CID 22226835.
    Grimes DA (2000). "Intrauterine device and upper-genital-tract infection". Lancet. 356 (9234): 1013–9. doi:10.1016/S0140-6736(00)02699-4. PMID 11041414. S2CID 7760222.
31. "Athena Hidden Dangers of the Copper Iud". 2021-10-13. Archived from the original on 2021-11-10. Retrieved 2021-11-11.
32. ^ Curtis KM, Tepper NK, Jatlaoui TC, et al. (July 2016). "U.S. Medical Eligibility Criteria for Contraceptive Use, 2016" (PDF). MMWR Recomm Rep. 65 (3): 1–103. doi:10.15585/mmwr.rr6503a1. PMID 27467196. Archived (PDF) from the original on 2020-10-16. Retrieved 2020-02-03.
33. Forthofer KV (2009). "A clinical review of the intrauterine device as an effective method of contraception". J Obstet Gynecol Neonatal Nurs. 38 (6): 693–8. doi:10.1111/j.1552-6909.2009.01067.x. PMID 19930283.
34. Lohr PA, Lyus R, Prager S (2017-06-01). "Use of intrauterine devices in nulliparous women". Contraception. 95 (6): 529–537. doi:10.1016/j.contraception.2016.08.011. ISSN 0010-7824. PMID 27591814. Archived from the original on 2021-08-28. Retrieved 2020-05-27.
35. Hubacher D, Schreiber CA, Turok DK, Jensen JT, Creinin MD, Nanda K, White KO, Dayananda I, Teal SB, Chen PL, Chen BA, Goldberg AB, Kerns JL, Dart C, Nelson AL (September 2022). "Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial". eClinicalMedicine. 51: 101554. doi:10.1016/j.eclinm.2022.101554. ISSN 2589-5370. PMC 9294241. PMID 35865736.
36. Sivin I, Stern J (1979). "Long-acting, more effective Copper T IUDs: a summary of U.S. experience, 1970–1975". Studies in Family Planning. 10 (10): 263–281. doi:10.2307/1965507. JSTOR 1965507. PMID 516121.
37. ^ "Birth Control Intrauterine Devices (IUDs)". Archived from the original on 2010-08-10. Author: Omnia M Samra. Last Editorial Review: 5/18/2006
38. "What To Expect During an IUD Insertion". Archived from the original on 2009-04-19. By Dawn Stacey M.Ed. Updated April 30, 2010
39. ACOG Committee Opinion 450 (December 2009). "Increasing the Use of Contraceptive Implants and Intrauterine Devices To Reduce Unintended Pregnancy". American Congress of Obstetricians and Gynecologists. Archived from the original on 2012-05-02. Retrieved 2012-06-28.{{cite web}}: CS1 maint: numeric names: authors list (link)
40. "Contraceptive coils (IUDs)". NetDoctor.co.uk. 2006. Archived from the original on 2006-07-17. Retrieved 2006-07-05.
41. Marketing e (2024-10-25). "Mona Lisa N.V." Website Mona Lisa. Retrieved 2024-10-25., a manufacturer of generic IUDs
42. "Data" (PDF). www.broadwaymed.co.nz. Archived from the original (PDF) on 2020-01-17. Retrieved 2020-07-10.
43. ^ "Guidance" (PDF). www.nhstaysideadtc.scot.nhs.uk. Archived (PDF) from the original on 2021-01-10. Retrieved 2020-07-10.
44. "Nova-T 380 IUD (Intrauterine Device)". www.mistrymedical.com. Archived from the original on 2020-03-30. Retrieved 2020-03-30.
45. "Neo-Safe T CU 380 Mini IUD". MidMeds Ltd. Archived from the original on 2020-03-30. Retrieved 2020-03-30.
46. ^ "Product information". Prosan (in Dutch). Archived from the original on 2020-03-30. Retrieved 2020-03-29.
47. "How big is Paragard?". Paragard IUD. Archived from the original on 2020-03-30. Retrieved 2020-03-29.
48. "SMB T 380A, Copper T IUD, SMB T 380A IUD, Copper T IUD Device". www.smbcorpn.com. Archived from the original on 2020-07-22. Retrieved 2020-07-21.
49. Wu S, Hu J, Wildemeersch D (February 2000). "Performance of the frameless GyneFix and the TCu380A IUDs in a 3-year multicenter, randomized, comparative trial in parous women". Contraception. 61 (2): 91–8. doi:10.1016/s0010-7824(00)00087-1. PMID 10802273.
50. D'Souza RE, Bounds W, Guillebaud J (April 2003). "Comparative trial of the force required for, and pain of, removing GyneFix versus Gyne-T380S following randomised insertion". J Fam Plann Reprod Health Care. 29 (2): 29–31. doi:10.1783/147118903101197494. PMID 12681034.
51. ^ Ortiz ME, Croxatto HB (June 2007). "Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action". Contraception. 75 (6 Suppl): S16‒S30. doi:10.1016/j.contraception.2007.01.020. PMID 17531610. p. S28:

    Conclusions
    Active substances released from the IUD or IUS, together with products derived from the inflammatory reaction present in the luminal fluids of the genital tract, are toxic for spermatozoa and oocytes, preventing the encounter of healthy gametes and the formation of viable embryos. The current data do not indicate that embryos are formed in IUD users at a rate comparable to that of nonusers. The common belief that the usual mechanism of action of IUDs in women is the destruction of embryos in the uterus is not supported by empirical evidence. The bulk of the data indicate that interference with the reproductive process after fertilization has taken place is exceptional in the presence of a T-Cu or LNG-IUD and that the usual mechanism by which they prevent pregnancy in women is by preventing fertilization.

52. Speroff L, Darney PD (2011). "Intrauterine contraception". A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 239–280. ISBN 978-1-60831-610-6. p. 246:

    Mechanism of action
    The contraceptive action of all IUDs is mainly in the intrauterine cavity. Ovulation is not affected, and the IUD is not an abortifacient. It is currently believed that the mechanism of action for IUDs is the production of an intrauterine environment that is spermicidal.
    Nonmedicated IUDs depend for contraception on the general reaction of the uterus to a foreign body. It is believed that this reaction, a sterile inflammatory response, produces tissue injury of a minor degree but sufficient to be spermicidal. Very few, if any, sperm reach the ovum in the fallopian tube… In women using copper IUDs, sensitive assays for human chorionic gonadotropin do not find evidence of fertilization. This is consistent with the fact that the copper IUD protects against both intrauterine and ectopic pregnancies.
    The copper IUD releases free copper and copper salts that have both a biochemical and morphological impact on the endometrium and also produce alterations in cervical mucus and endometrial secretions... An additional spermicidal effect probably takes place in the cervical mucus.

53. Jensen JT, Mishell DR Jr (2012). "Family planning: contraception, sterilization, and pregnancy termination". In Lentz GM, Lobo RA, Gershenson DM, Katz VL (eds.). Comprehensive gynecology. Philadelphia: Mosby Elsevier. pp. 215–272. ISBN 978-0-323-06986-1. p. 259:

    Intrauterine devices
    Mechanisms of action
    The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence... Because concern over the mechanism of action represents a barrier to acceptance of this important and highly effective method for some women and some clinicians, it is important to point out that there is no evidence to suggest that the mechanism of action of IUDs is abortifacient... the principal mechanism of action of the copper T 380A IUD is to interfere with sperm action, preventing fertilization of the ovum.

54. ESHRE Capri Workshop Group (May–June 2008). "Intrauterine devices and intrauterine systems". Human Reproduction Update. 14 (3): 197‒208. doi:10.1093/humupd/dmn003. PMID 18400840. p. 199:

    Mechanisms of action
    Thus, both clinical and experimental evidence suggests that IUDs can prevent and disrupt implantation. It is unlikely, however, that this is the main IUD mode of action, … The best evidence indicates that in IUD users it is unusual for embryos to reach the uterus.
    In conclusion, IUDs may exert their contraceptive action at different levels. Potentially, they interfere with sperm function and transport within the uterus and tubes. It is difficult to determine whether fertilization of the oocyte is impaired by these compromised sperm. There is sufficient evidence to suggest that IUDs can prevent and disrupt implantation. The extent to which this interference contributes to its contraceptive action is unknown. The data are scanty and the political consequences of resolving this issue interfere with comprehensive research.
    p. 205:
    Summary
    IUDs that release copper or levonorgestrel are extremely effective contraceptives... Both copper IUDs and levonorgestrel-releasing IUSs may interfere with implantation, although this may not be the primary mechanism of action. The devices also create barriers to sperm transport and fertilization, and sensitive assays detect hCG in less than 1% of cycles, indicating that significant prevention must occur before the stage of implantation.

55. Speroff L, Darney PD (2011). "Special uses of oral contraception: emergency contraception, the progestin-only minipill". A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 153–166. ISBN 978-1-60831-610-6. p. 157:

    Emergency postcoital contraception
    Other methods
    Another method of emergency contraception is the insertion of a copper IUD, anytime during the preovulatory phase of the menstrual cycle and up to 5 days after ovulation. The failure rate (in a small number of studies) is very low, 0.1%. This method definitely prevents implantation, but it is not suitable for women who are not candidates for intrauterine contraception, e.g., multiple sexual partners or a rape victim. The use of a copper IUD for emergency contraception is expensive, but not if it is retained as an ongoing method of contraception.

56. Trussell J, Schwarz EB (2011). "Emergency contraception". In Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 113–145. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. p. 121:

    Mechanism of action
    Copper-releasing IUCs
    When used as a regular or emergency method of contraception, copper-releasing IUCs act primarily to prevent fertilization. Emergency insertion of a copper IUC is significantly more effective than the use of ECPs, reducing the risk of pregnancy following unprotected intercourse by more than 99%. This very high level of effectiveness implies that emergency insertion of a copper IUC must prevent some pregnancies after fertilization.
    Pregnancy begins with implantation according to medical authorities such as the US FDA, the National Institutes of Health and the American College of Obstetricians and Gynecologists (ACOG).

57. ^ Brigid Fitzgerald Reading. "Growth in World Contraceptive Use Stalling; 215 Million Women's Needs Still Unmet". Earth Policy Institute. Archived from the original on 2012-12-03. Retrieved 2013-10-04.
58. Sonfield, Adam (2012). "Popularity Disparity: Attitudes About the IUD in Europe and the United States". The Guttmacher Institute. Archived from the original on 2010-03-07.
59. "A History of Birth Control Methods". Planned Parenthood. June 2002. Archived from the original on 2008-05-17. Retrieved 2007-10-14., which cites:
    • Thomas P (1988-03-14). "Contraceptives". Medical World News. 29 (5): 48.
    • Bullough VL, Bullough, Bonnie (1990). Contraception: A Guide to Birth Control Methods. Buffalo, NY: Prometheus Books. ISBN 9780879755898.
60. ^ Lynch CM. "History of the IUD". Contraception Online. Baylor College of Medicine. Archived from the original on 2006-01-27. Retrieved 2006-07-09.
61. ^ "Evolution and Revolution: The Past, Present, and Future of Contraception". Contraception Online (Baylor College of Medicine). 10 (6). February 2000. Archived from the original on September 26, 2006.
62. Bradley J (August 1998). "Ultrasound Interactive Case Study: Ring IUD". OBGYN.net. Archived from the original on 2006-01-17. Retrieved 2006-07-09. (Has pictures of various IUD designs.)
63. Kaufman J (May–Jun 1993). "The cost of IUD failure in China". Studies in Family Planning. 24 (3): 194–6. doi:10.2307/2939234. JSTOR 2939234. PMID 8351700.
64. Van Kets H (1997). C. Coll Capdevila, L. Iglesias Cortit, G. Creatsas (eds.). "Importance of intrauterine contraception". Contraception Today, Proceedings of the 4th Congress of the European Society of Contraception. The Parthenon Publishing Group. pp. 112–116. Archived from the original on 2006-08-10. Retrieved 2006-07-09. (Has pictures of many IUD designs, both historic and modern.)
65. Sivin I (1993). "Another look at the Dalkon Shield: meta-analysis underscores its problems". Contraception. 48 (1): 1–12. doi:10.1016/0010-7824(93)90060-K. PMID 8403900.
66. Mintz, Morton (January 15, 1986). "A Crime Against Women. A. H. Robins and the Dalkon Shield". Multinational Monitor. 7 (1). Archived from the original on October 3, 2006.
67. Salem R (February 2006). "New Attention to the IUD: Expanding Women's Contraceptive Options To Meet Their Needs". Popul Rep B (7). Archived from the original on 2007-10-13.
68. "Paragard® (intrauterine copper contraceptive) - CooperSurgical". www.coopersurgical.com. 2023-06-28. Retrieved 2023-11-29.
69. "IUD Birth Control | Info About Mirena & Paragard IUDs". www.plannedparenthood.org. Retrieved 2023-11-29.
70. "The TCu380A Intrauterine Contraceptive Device (IUD): Specification, Prequalification and Guidelines for Procurement, 2010" (PDF).
71. Center for Drug Evaluation and Research. "Approval Package for Application Number 18-680" (PDF).
72. "Health: Birth Control; U.S. Experts Applaud Growth in Options for Contraception". The New York Times.
73. "20f". www.sec.gov. 2005-06-29. Retrieved 2023-11-29.
74. "Duramed Pharmaceuticals, Inc. Completes Acquisition Of FEI Company Women's Health And ParaGard(R) IUD Product". BioSpace. Retrieved 2023-11-29.
75. Processing P (2008-12-23). "Teva Completes Acquisition of Barr". Pharmaceutical Processing World. Retrieved 2023-11-29.
76. "The Cooper Companies Completes Acquisition of Paragard IUD From Teva". Cooper Companies. Archived from the original on 2021-11-24. Retrieved 2021-11-24.

• Medicine

• Intrauterine contraception
• World Health Organization essential medicines